Clinical Trial: A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07018323) titled 'A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease' on May 14.

Brief Summary: This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.

Study Start Date: July, 2025

Study Type: INTERVENTIONAL

Condition: Graves' Disease

Intervention: DRUG: IMVT-1402

Dose 1 for 26 weeks

DRUG: IMVT-1402

Dose 2 for 26 weeks

DRUG: Placebo

For 26 weeks

Recruitment S...